Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
response rate
1~2 year
Yes
Korea: Food and Drug Administration
2009-09-090
NCT01099540
April 2010
March 2013
Name | Location |
---|